Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk

被引:0
|
作者
Ionescu, Vlad Alexandru [1 ,2 ]
Gheorghe, Gina [1 ,2 ]
Bacalbasa, Nicolae [3 ,4 ]
Diaconu, Camelia Cristina [1 ,2 ,5 ]
机构
[1] Univ Med & Pharm Carol Davila Bucharest, Fac Med, Bucharest 050474, Romania
[2] Clin Emergency Hosp Bucharest, Internal Med Dept, Bucharest 105402, Romania
[3] Fundeni Clin Inst, Ctr Digest Dis & Liver Transplantat, Dept Visceral Surg, Bucharest 022328, Romania
[4] Univ Med & Pharm Carol Davila, Dept Surg, Bucharest 050474, Romania
[5] Acad Romanian Scientists, Bucharest 050085, Romania
关键词
MASLD; cardiovascular risk; pathophysiology; myocardial ischemia; heart failure; atrial fibrillation; NONALCOHOLIC FATTY LIVER; EPICARDIAL ADIPOSE-TISSUE; AORTIC-VALVE SCLEROSIS; SUPERFAMILY MEMBER 2; INSULIN-RESISTANCE; HEPATIC STEATOSIS; ATRIAL-FIBRILLATION; GENERAL-POPULATION; GENETIC-VARIATION; OXIDATIVE STRESS;
D O I
10.3390/biom15020163
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) is correlated with an increased cardiovascular risk, independent of other traditional risk factors. The mechanisms underlying this pathogenic link are complex yet remain incompletely elucidated. Among these, the most significant are visceral adiposity, low-grade inflammation and oxidative stress, endothelial dysfunction, prothrombotic status, insulin resistance, dyslipidemia and postprandial hyperlipemia, gut dysbiosis, and genetic mutations. Cardiovascular diseases are the leading cause of death in patients with MASLD. These patients have an increased incidence of coronary artery disease, carotid artery disease, structural and functional cardiac abnormalities, and valvulopathies, as well as arrhythmias and cardiac conduction disorders. In this review, we present the latest data on the association between MASLD and cardiovascular risk, focusing on the pathogenic mechanisms that explain the correlation between these two pathologies. Given the high rates of cardiovascular morbidity and mortality among patients with MASLD, we consider it imperative to raise awareness of the risks associated with this condition within the general population. Further research is essential to clarify the mechanisms underlying the increased cardiovascular risk linked to MASLD. This understanding may facilitate the identification of new diagnostic and prognostic biomarkers for these patients, as well as novel therapeutic targets.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [2] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [3] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [4] Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
    Mellemkjaer, Anders
    Kjaer, Mikkel Breinholt
    Haldrup, David
    Gronbaek, Henning
    Thomsen, Karen Louise
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 28 - 34
  • [5] Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
    Zheng, Haixiang
    Sechi, Leonardo Antonio
    Navarese, Eliano Pio
    Casu, Gavino
    Vidili, Gianpaolo
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [6] Cardiovascular Disease Risk Is Increased In Adolescents With Metabolic Dysfunction-associated Steatotic Liver Disease
    Short, Kevin R.
    Palle, Sirish K.
    Tryggestad, Jeanie B.
    Hellman, Diana A.
    Sciarrillo, Christina M.
    Emerson, Sam R.
    Friedman, Jacob E.
    MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2024, 56 (10) : 680 - 680
  • [7] Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis
    Saidi, A. N.
    Theel, W. B.
    Burggraaf, B.
    van der Lelij, A. J.
    Grobbee, D. E.
    van Zeben, J. D.
    van der Zwan-van Beek, E.
    Rauh, S. P.
    Cabezas, M. Castro
    CLINICAL RHEUMATOLOGY, 2025, : 1485 - 1492
  • [8] Clarifications and enhancements for cardiovascular risk study in metabolic dysfunction-associated steatotic liver disease
    Wu, Yinfang
    Xu, Weixing
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2025, 132 : 158 - 159
  • [9] Cardiovascular risk assessment in inflammatory bowel disease with metabolic dysfunction-associated steatotic liver disease
    Garcia-Mateo, Sandra
    Martinez-Dominguez, Samuel J.
    Gargallo-Puyuelo, Carla J.
    Gallego, Beatriz
    Alfambra, Erika
    Aso, Maria C.
    Martinez-Micaelo, Neus
    Amigo, Nuria
    Martinez-Garcia, Javier
    Baptista, Pedro M.
    Sanz, Borja
    Ballesta, Sara
    Espinosa, Judith
    Tejero, Carlos
    Gomollon, Fernando
    MEDICINA CLINICA, 2024, 162 (09): : 409 - 416
  • [10] Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults
    Chung, Goh Eun
    Yu, Su Jong
    Yoo, Jeong-Ju
    Cho, Yuri
    Lee, Kyu-na
    Shin, Dong Wook
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Han, Kyungdo
    Cho, Eun Ju
    SCIENTIFIC REPORTS, 2025, 15 (01):